New Injection Repairs Arthritic Joints in Weeks

Millions of people with arthritis may soon have a treatment that helps their damaged joints heal themselves without major surgery.

Researchers at the University of Colorado Boulder and partner institutions developed two experimental therapies that reversed osteoarthritis in animals within just four to eight weeks. The breakthrough is promising enough that the team received up to $33.5 million in federal funding and is now advancing to the next phase of development.

Osteoarthritis affects one in six people over age 30 worldwide, making it the third most common disease in the United States. The condition breaks down cartilage that prevents bones from rubbing together, causing severe pain and limiting movement.

Right now, patients have limited options: manage pain with medication or undergo expensive joint replacement surgery. There is no cure.

The Colorado team is changing that with two approaches. One is a single injection that slowly releases healing medicine directly into the joint over several months. The other is a biomaterial that can be delivered through a small incision and hardens in place, attracting the body's own cells to rebuild damaged cartilage and bone.

In animal studies, arthritic joints returned to a healthy state within weeks. When researchers repaired holes in bone or cartilage, they saw what lead investigator Dr. Stephanie Bryant described as "full regeneration and repair of the defect."

The therapies also showed strong healing effects in human cells taken from patients undergoing joint replacement surgery. Bryant, a professor of chemical and biological engineering at CU Boulder, said their goal goes beyond pain relief.

"Our goal is not just to treat pain and halt progression, but to end this disease," Bryant explained.

The Ripple Effect

The impact could transform care for everyone from older adults struggling with daily activities to young athletes forced to quit sports because of chronic joint pain.

Dr. Evalina Burger, chair of orthopedics at CU Anschutz, noted that many patients currently face an impossible choice. "At the moment, the options for many patients are either a massive, expensive surgery or nothing. There's not a lot in between," she said.

The new treatments could offer patients in early stages of osteoarthritis a low-cost, single-dose therapy that keeps joints healthy for years. Those with more serious damage might receive treatment during a single doctor visit with a quick recovery.

The research is part of the Advanced Research Projects Agency for Health's program to develop minimally invasive therapeutics that fully regenerate damaged joints. After successfully completing the first phase, the team is now moving into phase two.

The researchers launched Renovare Therapeutics Inc. to help bring the technology to patients and plan to publish their animal study results later this year. If future studies continue showing positive results, clinical trials could begin in as little as 18 months.